A placebo controlled RCT of canakinumab in 31 Adult Stills pts with arthritis showed responders (by DAS28) had signif reductions in calprotectin, IL-1RA, IL-18, IL-at wk 4. Unfortunately: didnt look at fever, rash, serositis, etc. https://t.co/p4Fohos2iU